CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

Core Insights - CytomX Therapeutics announced positive interim Phase 1 clinical data for CX-2051 in advanced colorectal cancer [3] - The company secured a $100 million financing from a leading group of healthcare investors [3] Financial Results - The company released its first quarter 2025 financial results alongside the announcement of the Phase 1 data [3] Clinical Development - The focus of the call was primarily on the Phase 1 data for CX-2051, indicating significant progress in the clinical pipeline [3]